Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzon

Executive Summary

Begins marketing Adagen, an orphan drug used in the treatment of Severe Combined Immunodeficiency Disease (SCID), which is fatal if untreated. Adagen costs $2,200 per vial in the U.S. and $3,000 outside the country. The company says "the price is based on the cost of the raw materials used to manufacture the drug, monitoring patients and meeting quality control regulatory standards." National Organization for Rare Disorders (NORD) Executive Director Abbey Meyers defended Enzon's pricing of the drug: "Unlike the blockbuster drugs masquerading as 'orphans' to keep out competition and making hundreds of millions of dollars, Adagen is a true orphan drug." Adagen received orphan status in May 1984; Enzon filed the NDA in January 1988. The drug has been available at no charge since its approval in March. According to Enzon, about 40 cases of ADA-deficient SCID are diagnosed annually worldwide ("The Pink Sheet" March 26, T&G-1).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018254

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel